特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

再生医療の世界市場:2020年~2024年

Regenerative Medicine Market by Technology and Geography - Forecast and Analysis 2020-2024

発行 TechNavio (Infiniti Research Ltd.) 商品コード 321466
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
再生医療の世界市場:2020年~2024年 Regenerative Medicine Market by Technology and Geography - Forecast and Analysis 2020-2024
出版日: 2020年02月04日 ページ情報: 英文 120 Pages
概要

世界の再生医療市場は、2020年から2024年の予測期間中に20%のCAGRで成長し、95億5,000万米ドルの規模に達する見込みです。同市場は、慢性疾患の有病率の増加に牽引されています。さらに、臨床試験の増加が市場成長を後押しすると予想されています。

当レポートでは、世界の再生医療市場について調査分析し、市場規模および成長率、市場動向、市場促進要因、課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

エグゼクティブサマリー

  • 市場概況

市場状況

  • 市場のエコシステム
  • バリューチェーン分析

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模:2019年
  • 市場の見通し:2019-2024年の予測

ファイブフォース分析

  • ファイブフォースサマリー
  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • ライバルの脅威
  • 市況

市場セグメンテーション:技術別

  • 市場セグメンテーション
  • 比較:技術別市場規模と予測2019-2024
  • 細胞および組織ベース
  • 遺伝子治療
  • 市場機会:技術別

顧客情勢

  • 概要

地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模と予測2019-2024
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会:地域別

成長要因、課題、および動向

  • 市場成長要因
  • 数量的成長要因-需要主導型成長
  • 数量的成長要因-供給主導型成長
  • 数量的成長要因-外部要因
  • 数量的成長要因-隣接市場での需要シフト
  • 価格上昇要因-インフレ
  • 価格上昇要因-低価格ユニットから高価格ユニットへの移行
  • 市場の課題
  • 市場動向

ベンダー情勢

  • 概要
  • ベンダー情勢
  • 情勢の革新

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Allergan Plc
  • Amgen Inc.
  • 日立化成
  • Integra LifeSciences Holdings Corp.
  • Medtronic Plc
  • MiMedx Group Inc.
  • Organogenesis Holdings Inc.
  • Smith & Nephew Plc
  • 武田薬品工業
  • Zimmer Biomet Holdings Inc.

付録

  • 調査範囲
  • 米ドルの通貨換算レート
  • 調査方法
  • 略語のリスト
目次
Product Code: IRTNTR41171

Technavio has been monitoring the global regenerative medicine market and it is poised to grow by USD 9.55 bn during 2020-2024, progressing at a CAGR of 20% during the forecast period. Our reports on global regenerative medicine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of chronic diseases.

In addition, increasing number of clinical trials is anticipated to boost the growth of the global regenerative medicine market as well.

Market Segmentation

Technavio's global regenerative medicine market is segmented as below:

Technology

  • Cell and tissue-based
  • Gene therapy

Geographic segmentation

  • North America
  • Europe
  • Asia
  • ROW

Key Trends for global regenerative medicine market growth

This study identifies increasing number of clinical trials as the prime reasons driving the global regenerative medicine market growth during the next few years.

Prominent vendors in global regenerative medicine market

We provide a detailed analysis of around 25 vendors operating in the global regenerative medicine market, including some of the vendors such as Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd. and Zimmer Biomet Holdings Inc. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavi's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Technology

  • Market segments
  • Comparison by Technology placement
  • Cell and tissue-based - Market size and forecast 2019-2024
  • Gene therapy - Market size and forecast 2019-2024
  • Market opportunity by Technology

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Allergan Plc
  • Amgen Inc.
  • Hitachi Chemical Co. Ltd.
  • Integra LifeSciences Holdings Corp.
  • Medtronic Plc
  • MiMedx Group Inc.
  • Organogenesis Holdings Inc.
  • Smith & Nephew Plc
  • Takeda Pharmaceutical Co. Ltd.
  • Zimmer Biomet Holdings Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 4
  • 5.Key Finding 5
  • 6.Key Finding 6
  • 7.Key Finding 7
  • 8.Market in focus
  • 9.Parent market
  • 10.Market characteristics
  • 11.Product / Service portfolio of key vendors included in the market definition
  • 12.Market segments
  • 13.Global - Market size and forecast 2019 - 2024 ($ million)
  • 14.Global market: Year-over-year growth 2019 - 2024 (%)
  • 15.Five forces analysis 2019 & 2024
  • 16.Bargaining power of buyers
  • 17.Bargaining power of suppliers
  • 18.Threat of new entrants
  • 19.Threat of substitutes
  • 20.Threat of rivalry
  • 21.Market condition - Five forces 2019
  • 22.Technology placement - Market share 2019-2024 (%)
  • 23.Comparison by Technology placement
  • 24.Cell and tissue-based - Market size and forecast 2019-2024 ($ million)
  • 25.Cell and tissue-based - Year-over-year growth 2019-2024 (%)
  • 26.Gene therapy - Market size and forecast 2019-2024 ($ million)
  • 27.Gene therapy - Year-over-year growth 2019-2024 (%)
  • 28. Market opportunity by Technology
  • 29.Customer landscape
  • 30.Market share by geography 2019-2024 (%)
  • 31.Geographic comparison
  • 32.North America - Market size and forecast 2019-2024 ($ million)
  • 33.North America - Year-over-year growth 2019-2024 (%)
  • 34.Europe - Market size and forecast 2019-2024 ($ million)
  • 35.Europe - Year-over-year growth 2019-2024 (%)
  • 36.Asia - Market size and forecast 2019-2024 ($ million)
  • 37.Asia - Year-over-year growth 2019-2024 (%)
  • 38.ROW - Market size and forecast 2019-2024 ($ million)
  • 39.ROW - Year-over-year growth 2019-2024 (%)
  • 40.Key leading countries
  • 41.Market opportunity by geography ($ million)
  • 42.Impact of drivers
  • 43.Impact of challenges
  • 44.Landscape disruption
  • 45.Industry risks
  • 46.Vendors covered
  • 47.Market positioning of vendors
  • 48.Allergan Plc - Overview (1/3)
  • 49.Allergan Plc - Overview (2/3)
  • 50.Allergan Plc - Overview (3/3)
  • 51.Allergan Plc - Business segments
  • 52.Allergan Plc - Key offerings
  • 53.Allergan Plc - Key customers
  • 54.Allergan Plc - Segment focus
  • 55.Amgen Inc. - Overview (1/3)
  • 56.Amgen Inc. - Overview (2/3)
  • 57.Amgen Inc. - Overview (3/3)
  • 58.Amgen Inc. - Business segments
  • 59.Amgen Inc. - Key offerings
  • 60.Amgen Inc. - Key customers
  • 61.Amgen Inc. - Segment focus
  • 62.Hitachi Chemical Co. Ltd. - Overview (1/3)
  • 63.Hitachi Chemical Co. Ltd. - Overview (2/3)
  • 64.Hitachi Chemical Co. Ltd. - Overview (3/3)
  • 65.Hitachi Chemical Co. Ltd. - Business segments
  • 66.Hitachi Chemical Co. Ltd. - Key offerings
  • 67.Hitachi Chemical Co. Ltd. - Key customers
  • 68.Hitachi Chemical Co. Ltd. - Segment focus
  • 69.Integra LifeSciences Holdings Corp. - Overview (1/3)
  • 70.Integra LifeSciences Holdings Corp. - Overview (2/3)
  • 71.Integra LifeSciences Holdings Corp. - Overview (3/3)
  • 72.Integra LifeSciences Holdings Corp. - Business segments
  • 73.Integra LifeSciences Holdings Corp. - Key offerings
  • 74.Integra LifeSciences Holdings Corp. - Key customers
  • 75.Integra LifeSciences Holdings Corp. - Segment focus
  • 76.Medtronic Plc - Overview (1/3)
  • 77.Medtronic Plc - Overview (2/3)
  • 78.Medtronic Plc - Overview (3/3)
  • 79.Medtronic Plc - Business segments
  • 80.Medtronic Plc - Key offerings
  • 81.Medtronic Plc - Key customers
  • 82.Medtronic Plc - Segment focus
  • 83.MiMedx Group Inc. - Overview (1/3)
  • 84.MiMedx Group Inc. - Overview (2/3)
  • 85.MiMedx Group Inc. - Overview (3/3)
  • 86.MiMedx Group Inc. - Product and service
  • 87.MiMedx Group Inc. - Key offerings
  • 88.MiMedx Group Inc. - Key customers
  • 89.MiMedx Group Inc. - Segment focus
  • 90.Organogenesis Holdings Inc. - Overview (1/3)
  • 91.Organogenesis Holdings Inc. - Overview (2/3)
  • 92.Organogenesis Holdings Inc. - Overview (3/3)
  • 93.Organogenesis Holdings Inc. - Business segments
  • 94.Organogenesis Holdings Inc. - Key offerings
  • 95.Organogenesis Holdings Inc. - Key customers
  • 96.Organogenesis Holdings Inc. - Segment focus
  • 97.Smith & Nephew Plc - Overview (1/3)
  • 98.Smith & Nephew Plc - Overview (2/3)
  • 99.Smith & Nephew Plc - Overview (3/3)
  • 100.Smith & Nephew Plc - Business segments
  • 101.Smith & Nephew Plc - Key offerings
  • 102.Smith & Nephew Plc - Key customers
  • 103.Smith & Nephew Plc - Segment focus
  • 104.Takeda Pharmaceutical Co. Ltd. - Overview (1/3)
  • 105.Takeda Pharmaceutical Co. Ltd. - Overview (2/3)
  • 106.Takeda Pharmaceutical Co. Ltd. - Overview (3/3)
  • 107.Takeda Pharmaceutical Co. Ltd. - Business segments
  • 108.Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 109.Takeda Pharmaceutical Co. Ltd. - Key customers
  • 110.Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 111.Zimmer Biomet Holdings Inc. - Overview (1/3)
  • 112.Zimmer Biomet Holdings Inc. - Overview (2/3)
  • 113.Zimmer Biomet Holdings Inc. - Overview (3/3)
  • 114.Zimmer Biomet Holdings Inc. - Product and service
  • 115.Zimmer Biomet Holdings Inc. - Key offerings
  • 116.Zimmer Biomet Holdings Inc. - Key customers
  • 117.Zimmer Biomet Holdings Inc. - Segment focus
  • 118.Currency conversion rates for US$
  • 119.Research Methodology
  • 120.Validation techniques employed for market sizing
  • 121.Information sources
  • 122.List of abbreviations